Indications of Neratinib

Extended Adjuvant Treatment for Early Breast Cancer

Neratinib is indicated as a monotherapy for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuvant therapy based on trastuzumab.

Advanced or Metastatic Breast Cancer

Neratinib in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2-based treatment regimens in the metastatic setting.

FDA，2021.06

Neratinib

Indications： It is indicated for the treatment of early-stage and advanced-stage HER2-positive breast cancer, and can be used as a monotherapy for adjuvant treatment or in combination with capecitabine for metasta

Scan code
Whatsapp

Medicine-related columns

Recommended Articles

There is no data under this category！

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More